FibroGen Inc (FGEN.OQ)
16 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||Chairman of the Board, Chief Executive Officer, Founder|
|53||2008||Chief Financial Officer, Vice President - Finance|
|66||2016||Senior Fellow, Clinical Development|
|54||2016||Chief Medical Officer|
- BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment
- BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients
- BRIEF-FibroGen Q4 Loss Per Share $0.27
- BRIEF-Fibrogen Inc reports Q3 loss per share $0.50
- BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease